We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Right prescription

6 March 2020 By Robyn Mak

The e-commerce group is injecting assets into a healthcare subsidiary, now worth a punchy $25 bln. It’s a bet that the coronavirus will accelerate reforms, like opening China’s $370 bln drug industry to web retailers. Alibaba’s scale could deliver a potent treatment to investors.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)